Citabol Drug Interactions

No specific interaction studies have been performed.
Radiotherapy: Concurrent (given together or ≤7days apart): Toxicity associated with this multimodality therapy is dependent on many different factors, including dose of gemcitabine, frequency of gemcitabine administration, dose of radiation, radiotherapy planning technique, the target tissue and target volume. The optimum regimen for safe administration of gemcitabine with therapeutic doses of radiation has not yet been determined in all tumor types.
Non-concurrent (given >7 days apart): Analysis of the data does not indicate any enhanced toxicity when gemcitabine is administered more than 7 days before or after radiation, other than radiation recall.
Radiation injury has been reported on targeted tissues (e.g. esophagitis, colitis and pneumonitis) in association with both concurrent and non‐ concurrent use of gemcitabine.
Others: Yellow fever and other live attenuated vaccines are not recommended due to the risk of system ic, possibly fatal, disease, particularly in immunosuppressed patients.
Incompatibilities: This medicinal product must not be mixed with other medicinal products.